<DOC>
	<DOC>NCT02504437</DOC>
	<brief_summary>The purpose of the present study is to evaluate the efficacy of the preconditioned autologous bone marrow mesenchymal stem cells for patients with ischemic heart diseases.</brief_summary>
	<brief_title>Therapy of Preconditioned Autologous BMMSCs for Patients With Ischemic Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Age under 75; Clinical diagnosis of acute Myocardial Infarction, chronic Myocardial Infarction and Ischemic Cardiomyopathy NYHA (New York Heart Association) grade: IIIIV, LVEF (left ventricular ejection fraction): 2550%; No infection diseases including HBV (hepatitis B virus), HCV (hepatitis C virus ), syphilis and AIDS; No psychiatric illnesses and speaking dysfunction; Informed consent. More than 75 years old; LVEF&lt;24%; Unstable hemodynamics, shock; Severe infection; Patients have tumor or other lethal diseases (expectation of life&lt;6 months); Radiation patients; hematopoietic malignancy including Haemophiliacs; Anemia (Hb&lt;100g/L); The other clinical trial participants within one month; Abnormal increasing of the blood biochemical indicators that is not explained by the conditions; Informed refusal.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>